RxDoctor Payments Data

Jennifer Turano, OD

Optometrist · Wilmington, DENPI 1770963449

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $25,857 of the $41,609 with a category attached, or 62.1%. Alcon accounts for 83.6% of it on its own, with 18 other manufacturers making up the rest. Reporting peaked in 2021 at $14,529 and has fallen 91.9% since, to $1,184 in 2025. Among optometrist clinicians in DE with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$41,609in general payments, 2019–2025

Across 145 payments — averaging $286.96 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Alcon$35K
  • Carl Zeiss Meditec, Inc.$4K
  • Carl Zeiss Meditec USA, Inc.$2K
  • Bausch & Lomb Americas Inc.$401
  • Valley Contax, Inc.$160
  • Kala Pharmaceuticals, Inc.$134
  • plus $665 from 13 others

What the payments were for

  • Consulting fees$25,85762%
  • Speaking & faculty fees$6,84516%
  • Travel & lodging$3,6309%
  • Food & beverage$5,08112%
  • Gifts$1970%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$41,609 in reported general payments places this provider in the 95th percentile of 146 optometrist providers in Delaware.

See all optometrist providers in Delaware

Medicare billing

Part B allowed, 2024
$36,603
Medicare patients
176
Services billed
427

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XiidraLifitegrast33$64,051
RestasisCyclosporine16$23,817
MieboPerfluorohexyloctane/Pf15$17,473
Latanoprost60$1,089
Brimonidine Tartrate11$561
Timolol Maleate19$323
Dorzolamide-TimololDorzolamide Hcl/Timolol Maleat14$206

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bausch & Lomb Americas Inc.Xiidra, Miebo$401$81,52448 claims
AbbVieRestasis$72$23,81716 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 146 optometrist providers in Delaware.

Other optometrist in Wilmington

See the full list for Delaware

Where these figures come from

Is this you, or does something look wrong? →